FDA Approves New Manufacturing Process for Simlandi

The regulatory decision doubles the active pharmaceutical ingredient yield per production batch for the drug.

Updated on Oct. 20, 2026 in Healthcare

FDA Approves New Manufacturing Process for Simlandi

Live Poll

Do you believe increased drug manufacturing capacity will lead to better access to medicine for patients?

The U.S. Food and Drug Administration has approved an updated manufacturing process for Simlandi, a biosimilar to the medication Humira. Following the news, shares of Alvotech rose by 7%.

Why it matters

The improved manufacturing process increases efficiency by requiring fewer production batches to meet drug supply needs. This expanded capacity allows Alvotech to better serve market demand while freeing up resources for other medicines currently in development.

The FDA-approved process doubles the yield of active pharmaceutical ingredient per production batch. This efficiency gain is expected to streamline output for the Humira biosimilar.

The players

Alvotech

This biotechnology company specializes in the development and manufacturing of high-quality biosimilar medicines for global markets.

U.S. Food and Drug Administration

This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.

The details

The approval covers a manufacturing facility located in Vatnsmýri, Reykjavík, which was previously authorized by the agency in October 2026. By increasing the yield per batch, the manufacturer can fulfill demand for its therapeutics with a more efficient operational footprint.

October 20, 2026: FDA approves the new Simlandi manufacturing process.
October 2026: FDA authorizes the new Vatnsmýri, Reykjavík manufacturing facility.

Biotech
Oct. 13
FDA Finalized Biosimilar Manufacturing Guidance
Cancer
Oct. 16
FDA Approves Enspryng for Thyroid Eye Disease
Cancer
Oct. 14
FDA Accepted Resubmission for Tabelecleucel

Market Landscape

This approval follows the regulatory framework established by the Biologics Price Competition and Innovation Act to facilitate biosimilar market entry. The shift positions the company to compete more aggressively in the high-demand biologics sector by improving production economics.

Increased production efficiency typically supports a more reliable supply of lower-cost biosimilar alternatives for patients prescribed Humira. Consumers may see fewer supply-chain interruptions as manufacturing capacity expands to meet demand.

The takeaway

Manufacturing efficiency is a critical driver for the commercial viability of biosimilar medications. By optimizing production, companies can maintain competitive pricing while scaling their portfolios of critical therapies.